2179 — Jiangsu Recbio Technology Share News
0.000.00%
Last trade - 00:00- HK$2.38bn
- HK$2.95bn
- CNY12.73m
China's Jiangsu Recbio jumps after saying comparative COVID vaccine study shows positive results
Brief: Jiangsu Recbio Technology Receives Approval By Stock Exchange For Listing Of 222.5 Mln H Shares
Brief: Jiangsu Recbio Technology Says Increased Capacity For First Phase Of HPV Vaccine Manufacturing
Brief: Jiangsu Recbio Technology Says Completed First Batch Of Subject Enrollment For Phase Iii Clinical Trial Of Recov Vaccine
Brief: Jiangsu Recbio Technology Says Positive Results Achieved For Primary Vaccination Phase II Study In Philippines
Brief: Jiangsu Recbio Technology Says Got Acceptance Of Application
Brief: Jiangsu Recbio Technology Co Subscribed For Principal-Guaranteed Structured Deposit Product From SPD Bank Worth RMB125 Mln
Brief: Jiangsu Recbio Technology Posts HY Loss Attributable RMB349.7 Million
Brief: Jiangsu Recbio Technology Says Acceptance By CSRC Of H Share Full Circulation Application Of Co
Brief: Jiangsu Recbio Technology Says Got Approval Of Comparative Study Between Recov & Mrna Vaccines By FDA In Philippines
Brief: Jiangsu Recbio Technology Says Board Approved Proposed Conversion Of 222.5 Mln Domestic Shares Of Co Into H Shares
Brief: Jiangsu Recbio Technology Says It Got Clinical Trial Approval For An Omicron Vaccine In Philippines
Brief: Jiangsu Recbio Technology Received Clinical Trial Approval For Its Recombinant Protein Covid-19 Vaccine, Recov From China's NMPA
Brief: Jiangsu Recbio Technology Received Approval From Uae For Phase Ii/Iii Clinical Trial Of Sequential Booster Vaccination For Recov
Yacht maker Ferretti rises in HK debut; Recbio, Redco shine